Equities research analysts at StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a research report issued on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
NBRV opened at $0.16 on Friday. The company has a current ratio of 2.81, a quick ratio of 2.01 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average price is $0.19 and its two-hundred day moving average price is $0.28. Nabriva Therapeutics has a 1-year low of $0.16 and a 1-year high of $1.40. The company has a market cap of $108.80 million, a price-to-earnings ratio of -0.20 and a beta of 1.49.
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.02. Nabriva Therapeutics had a negative net margin of 131.91% and a negative return on equity of 95.18%. The firm had revenue of $9.19 million for the quarter, compared to the consensus estimate of $8.53 million. On average, analysts expect that Nabriva Therapeutics will post -0.68 EPS for the current fiscal year.
Hedge Funds Weigh In On Nabriva Therapeutics
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.